I now have comprehensive, high-quality content from multiple authoritative textbooks. Let me compile the complete answer.
Organophosphate (OP) Poisoning - Basics to Clinical
1. Overview and Epidemiology
Organophosphates (OPs) are phosphoric acid esters used widely as agricultural insecticides (malathion, parathion, chlorpyrifos, diazinon), veterinary antiparasitics, and as precursors to chemical warfare nerve agents (sarin, VX, tabun). They are the most common class of insecticide resulting in healthcare attendance worldwide.
- Deliberate self-poisoning is the most common cause globally (especially in South and Southeast Asia)
- Accidental exposure occurs in agricultural and industrial settings (sprayers, spills during transport)
- Routes of absorption: inhalation, transdermal, transconjunctival, mucous membrane, and GI
Common compounds by potency:
- High potency (mostly agricultural): parathion, azinphos-methyl
- Intermediate: coumaphos, trichlorfon
- Lower potency: malathion, diazinon
2. Mechanism of Action (Pharmacology/Biochemistry)
AChE Inhibition
OPs act as true hemisubstrates for acetylcholinesterase (AChE). They phosphorylate the active-center serine residue of AChE, forming an extremely stable phosphorylated enzyme complex. This irreversibly inhibits the enzyme.
Normal AChE function: rapidly hydrolyzes acetylcholine (ACh) at nerve synapses and neuromuscular junctions. When inhibited, ACh accumulates and overstimulates cholinergic receptors everywhere.
Two types of cholinesterase affected:
- Acetylcholinesterase (true/RBC cholinesterase) - in erythrocyte membranes, nervous tissue, skeletal muscle
- Plasma cholinesterase (pseudocholinesterase/butyrylcholinesterase) - in serum, liver, pancreas, heart, brain
The "Aging" Process
- The term aging describes the permanent, irreversible binding of the OP to cholinesterase after loss of one alkyl group from the phosphorylated enzyme
- Time to aging varies widely: from minutes to >24 hours depending on the compound
- Once aging occurs, new AChE must be resynthesized over weeks - antidotes (oximes) are only effective before aging occurs
OP vs. Carbamates
| Feature | Organophosphates | Carbamates |
|---|
| Binding to AChE | Irreversible (phosphorylation) | Reversible (carbamoylation) |
| Duration of toxicity | Weeks | Hours |
| Aging | Yes | No |
| Oxime (2-PAM) use | Yes | Not recommended |
| Clinical course | Longer, more severe | Shorter, less severe |
3. Pathophysiology
ACh accumulation leads to overstimulation of all cholinergic receptor types:
A. Muscarinic receptors (Parasympathetic nerve endings, smooth muscle, glands)
- Sweat glands (sympathetic but cholinergic), salivary/lacrimal/bronchial glands
- GI smooth muscle
- Heart (SA node, AV node)
B. Nicotinic receptors
- NMJ - skeletal muscle (fasciculations → paralysis)
- Autonomic ganglia - both sympathetic and parasympathetic (ganglionic stimulation)
C. CNS
- Both muscarinic and nicotinic receptors in brain
4. Clinical Features - The Four Syndromes
Syndrome 1: Acute Cholinergic Crisis (most common)
Most patients are symptomatic within 8 hours, nearly all within 24 hours.
Divided into three receptor-based categories:
Muscarinic Effects (SLUDGE + Killer Bs mnemonic)
SLUDGE:
| Letter | Effect |
|---|
| S | Salivation |
| L | Lacrimation |
| U | Urinary incontinence |
| D | Defecation |
| G | GI pain/cramps |
| E | Emesis |
The "Killer Bs" (most life-threatening):
- Bradycardia
- Bronchorrhea
- Bronchospasm
Additional muscarinic: miosis (classic), diaphoresis, increased GI motility, urinary incontinence
Nicotinic Effects
- Muscle fasciculations, cramps, weakness
- Diaphragm weakness → respiratory failure
- Stimulation at sympathetic ganglia/adrenal medulla: tachycardia, hypertension, mydriasis, pallor (may oppose muscarinic effects - mixed picture is common)
Note: In most patients, parasympathetic stimulation predominates, but mixed autonomic signs are frequent. Miosis is typical, but mydriasis can occur from nicotinic stimulation.
CNS Effects
- Anxiety, restlessness, emotional lability
- Tremor, headache, dizziness
- Confusion, delirium, hallucinations
- Seizures, coma
Cause of Death
Death is primarily from respiratory failure - the combination of:
- Bronchorrhea (muscarinic)
- Bronchospasm (muscarinic)
- Respiratory muscle paralysis (nicotinic)
- CNS depression (central)
Syndrome 2: Intermediate Syndrome
- Onset: 24-96 hours after acute cholinergic crisis resolves
- Mechanism: Neuromuscular transmission failure (more nicotinic than muscarinic)
- Features: Proximal limb weakness, neck flexor weakness, cranial nerve palsies, respiratory muscle failure
- Risk: Can cause sudden death from respiratory failure
- NOT effectively treated with standard atropine/2-PAM protocol - requires mechanical ventilation
- Most commonly reported with fenthion, dimethoate, monocrotophos
Syndrome 3: Organophosphate-Induced Delayed Polyneuropathy (OPIDP)
- Onset: 2-3 weeks after acute exposure
- Mechanism: Phosphorylation and inhibition of neuropathy target esterase (NTE) - distinct from AChE - causing axonal degeneration and demyelination of the longest nerves
- Features: Burning/tingling in feet → motor weakness → ascending ataxia, gait abnormality → can extend to hands and autonomic system
- Associated compounds: triorthocresyl phosphate (TOCP), leptophos, trichlorfon, methamidophos
- No specific treatment - supportive care only; long-term prognosis variable
Syndrome 4: Chronic Toxicity
- Low-level, repeated exposures (farm workers, manufacturing plant workers)
- Altered neurologic/cognitive function, psychological symptoms
- Associated with low arylesterase activity and neurologic complaints (Gulf War veterans)
5. Diagnosis
Clinical Diagnosis
Diagnosis is primarily clinical - do not withhold treatment pending lab confirmation.
Classic triad: miosis + bronchorrhea + muscle fasciculations in the right exposure context.
Laboratory Tests
| Test | Finding |
|---|
| RBC cholinesterase | Reflects AChE inhibition in neural tissue; more specific |
| Plasma cholinesterase | Easier to measure, drops earlier; less specific (affected by liver disease, pregnancy, succinylcholine) |
| Both | >50% reduction from baseline is clinically significant; baseline values needed for interpretation |
- Routine labs may show: pancreatitis, hypo/hyperglycemia, leukocytosis, elevated LFTs
- ECG changes: QT prolongation, ST changes, peaked T waves, AV block, torsades de pointes, VT/VF
- CXR: pulmonary edema in severe cases
- EMG: can identify and quantify AChE inhibition at NMJ
6. Management
Step 1: Decontamination (PRIORITY - do this first/simultaneously)
- Healthcare workers must wear protective clothing, neoprene/nitrile gloves (NOT latex) - secondary contamination is a real risk
- Remove and bag all patient clothing as hazardous waste
- Wash patient thoroughly with soap and water (scalp, hair, fingernails, skin folds, conjunctivae)
- Contaminated water runoff = hazardous material
- No transport by helicopter (risk to flight crew)
Step 2: Airway & Breathing
- Immediate airway protection - most critical intervention
- High-flow 100% oxygen
- Early intubation for respiratory compromise
- Treat bronchospasm with bronchodilators
- Avoid succinylcholine (prolonged paralysis due to pseudocholinesterase inhibition), ester anesthetics, and beta-blockers
Step 3: Atropine (Antimuscarinic - the primary antidote)
Mechanism: Competitive antagonist at muscarinic receptors. Does NOT reverse nicotinic effects (paralysis).
Dosing (adults):
- Initial: 1.2-3.0 mg IV (0.05 mg/kg in children)
- Double dose every 5 minutes until adequate atropinization
- Can require 200-500 mg in the first hour in severe poisoning
- Once stabilized: continuous infusion at 10-20% of the total loading dose per hour (typical: 0.4-4 mg/h IV)
Endpoint of adequate atropinization ("dry" endpoint):
- Clear chest on auscultation (no crackles/wheezes)
- Heart rate >80 bpm
- Systolic BP >80 mmHg
- Dry oral mucosa, reduced salivation
Important: Tachycardia and mydriasis at these doses are NOT reasons to stop - the endpoint is drying of secretions, NOT heart rate or pupil size.
Atropine toxicity signs (over-atropinization to avoid): absent bowel sounds, hyperthermia, delirium.
Step 4: Pralidoxime (2-PAM) / Oximes (AChE Reactivator)
Mechanism: Binds the OP-cholinesterase complex, causing a conformational change that allows cholinesterase to resume normal function. Reactivates BOTH muscarinic and nicotinic receptor effects (the only agent that can reverse muscle paralysis).
Key rule: Must be given before aging occurs - ideally within 24-48 hours of exposure.
Dosing:
- Adults: 30 mg/kg IV (up to 1-2 g) over 15-30 min
- Children: 25-50 mg/kg IV (up to 1 g)
- Followed by continuous infusion: 8 mg/kg/h for 24-48 hours
- Alternative: 2 g bolus → 500 mg/h for up to 7 days
Other oximes worldwide: TMB-4 (trimedoxime), toxogonin, methoxime, HI-6
Indications: respiratory depression, muscle fasciculations, seizures, dysrhythmias, hemodynamic instability, or large atropine requirements
Step 5: Seizures
- Benzodiazepines IV (diazepam, lorazepam, midazolam)
- Phenytoin is not effective for OP-induced seizures (cholinergic mechanism, not sodium channel)
- Intubation if persistent seizures with respiratory compromise
Step 6: Other Measures
| Intervention | Status |
|---|
| Activated charcoal | No proven benefit |
| Gastric lavage | No proven benefit |
| Magnesium sulfate | Some evidence of benefit - may be considered |
| Calcium channel blockers | Some evidence of benefit |
| Glycopyrrolate | Alternative antimuscarinic (does not cross BBB) |
7. Special Considerations
Military / Nerve Agents (Sarin, VX, Tabun)
- Same mechanism as OP pesticides but far more potent and faster acting
- Often rapid or near-instantaneous symptom onset
- Military uses auto-injectors (atropine + 2-PAM together)
- Pretreatment: pyridostigmine (reversible AChE inhibitor, "protects" AChE from irreversible binding)
Carbamates vs. OPs
- Carbamate poisoning is similar clinically but shorter duration
- Do NOT give pralidoxime for carbamates (can worsen toxicity)
Pediatric Notes (from Harriet Lane Handbook)
- Pralidoxime (use with atropine)
- Atropine: 0.05 mg/kg IV (no minimum dose restriction in severe poisoning)
8. Summary Table
| Feature | Details |
|---|
| Mechanism | Irreversible AChE inhibition via phosphorylation |
| Accumulates | Acetylcholine at all cholinergic synapses |
| Mnemonic | SLUDGE + Killer Bs (muscarinic); fasciculations/paralysis (nicotinic) |
| Syndromes | Acute (0-24h), Intermediate (1-4 days), Delayed neuropathy (2-3 wks), Chronic |
| Primary antidote | Atropine (for muscarinic effects) |
| Secondary antidote | Pralidoxime/2-PAM (reactivates AChE - both M and N effects) |
| Seizures | Benzodiazepines |
| Cause of death | Bronchorrhea + bronchospasm + respiratory muscle paralysis |
| Aging | Irreversible after hours to days - oximes useless after aging |
9. Recent Evidence (2024-2026)
Two recent systematic reviews are worth noting:
-
Glycopyrrolate in OP poisoning (Rashid et al., 2025 - PMID 38797902): glycopyrrolate is being studied as an alternative/adjunct antimuscarinic to atropine, particularly where it may avoid CNS atropine toxicity since it does not cross the blood-brain barrier.
-
Umbrella Review of OP therapeutic interventions (Chauhan et al., 2026 - PMID 42258859 - West J Emerg Med): the most current evidence synthesis (2026) reviewing all systemic reviews on OP treatment. This is the most up-to-date resource on the topic.
Sources:
- Tintinalli's Emergency Medicine, 9th Ed. - Chapter 201 (Organophosphates)
- Rosen's Emergency Medicine, Concepts and Clinical Practice - Chapter 152
- Goodman & Gilman's The Pharmacological Basis of Therapeutics, Chapter 12
- Katzung's Basic and Clinical Pharmacology, 16th Ed. - Chapter 55
- Bradley and Daroff's Neurology in Clinical Practice
- Harriet Lane Handbook, 23rd Ed. (Pediatric dosing)